Lightnews — Scholar-powered news

CyPath Lung @cypathlung.bsky.social · 31m

Day 2 at #CHEST2025! Great conversations with clinicians & researchers advancing noninvasive lung diagnostics.
Our team at Booth 2242 is sharing how #CyPathLung uses flow cytometry + #AI to support earlier, more accurate detection of lung cancer.
#bioAffinityTechnologies #LungHealth #Diagnostics

CyPath Lung @cypathlung.bsky.social · 1d

Big week at #CHEST2025!
Dr. Rossella Titone shares new research showing how CyPath® Lung stays accurate from sample to result. Proud of Dr. Titone, Dr. Downie & Dr. Elzi for representing!

CyPath Lung @cypathlung.bsky.social · 1d

CHEST 2025 is underway.
#CHEST #CyPathLung #earlylungcancerdetection #lungcancer #BIAF

CyPath Lung @cypathlung.bsky.social · 4d

AI is revolutionizing cancer detection. The USPTO plans to grant bioAffinity Technologies a patent for our AI-powered flow cytometry platform that detects lung cancer with precision and consistency. Learn more: bit.ly/42N8CAq
#CyPathLung #cancerdiagnostics #patent #AI

bit.ly

Reposted by CyPath Lung

American Thoracic Society (ATS) @atscommunity.bsky.social · 21d

The ATS and CAPC are proud to introduce a new collaborative series of seven modules on ATS Ed+ for clinicians treating patients with serious illnesses. Earn CME! #pallipulm @anandiyermd.bsky.social @donsullivan.bsky.social @pallipulm.bsky.social

Learn more: atsedplus.thoracic.org/capc/palliat...

11 6

CyPath Lung @cypathlung.bsky.social · 26d

On World Lung Day, we honor patients and families and look forward with hope. CyPath® Lung is committed to earlier detection, so every patient can have more time and more moments.
#WorldLungDay #LungHealth #EarlyDetection #CyPathLung

CyPath Lung @cypathlung.bsky.social · 28d

Indeterminate lung nodules don’t have to mean uncertainty.
CyPath® Lung is a noninvasive sputum test that uses flow cytometry to deliver:
✅92% sensitivity
✅87% specificity
Fewer unnecessary procedures.
Clearer, faster answers.
#LungCancer #EarlyDetection #CyPathLung

CyPath Lung @cypathlung.bsky.social · Sep 11

CyPath® Lung helped detect a malignancy in ground-glass nodules in a 66-year-old patient with a smoking history, supporting earlier detection and better care.
Watch Dr. Guda’s interview: www.cypathlung.com

#LungCancer #EarlyDetection #CyPathLung #PhysicainHighlights

CyPath Lung @cypathlung.bsky.social · Sep 9

Ground-glass nodules often mean years of “watchful waiting.” In a new case, CyPath® Lung delivered actionable results that led to timely lung cancer diagnosis and treatment.
Read more: bit.ly/3JNK181
#LungCancer #Diagnostics #CyPathLung

Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules - bioAffinity

bioAffinity Technologies’ noninvasive diagnostic shifted the course of care from watchful waiting for up to 5 years to confirmed malignancy and immediate treatment SAN ANTONIO, TX – September 9, 2025 ...

bit.ly

CyPath Lung @cypathlung.bsky.social · Sep 3

We are honored to be featured in U.S. Medicine. New issue includes a story on the economic impact of our #CyPathLung test for #lungcancer.
See our press release at bit.ly/47tdq12
See the US Medicine story at bit.ly/41XHLRR
#innovation #pulmonology #veterans

CyPath Lung @cypathlung.bsky.social · Aug 29

Now on the Federal Supply Schedule (FSS/GSA Contract #36F79725D0005), CyPath® Lung is available to VA providers nationwide, supporting better outcomes for veterans.
🔗 www.precisionpath.us/government-procurement/

FSS/VA Clients - Precision Pathology

www.precisionpath.us

CyPath Lung @cypathlung.bsky.social · Aug 29

Proud to see CyPath® Lung featured in U.S. Medicine’s August pulmonary issue.
Our noninvasive test can help veterans, 3x more likely to qualify for lung cancer screening, by improving detection, reducing unnecessary follow-ups & ⬇️costs.
📖 bit.ly/4mKrTKO
#LungCancer #VeteransHealth #CyPathLung

New Test Shows Promise for Improving Lung Cancer Detection, Reducing Costs for VA - U.S. Medicine

Lung cancer is the leading cause of cancer deaths in the United States. Early detection is vital, especially for veterans, who face a disproportionately high risk of lung cancer due to higher rates of...

bit.ly

1

CyPath Lung @cypathlung.bsky.social · Aug 28

Indeterminate lung nodules can be difficult to assess by CT or PET imaging. CyPath® Lung detects cancer in nodules <20mm with 92% sensitivity & 87% specificity which helps physicians catch malignancy earlier for better patient outcomes. bit.ly/IsraelGarcia
#CyPathLung #LungCancer #EarlyDetection

CyPath Lung @cypathlung.bsky.social · Aug 18

Wrapped up #AABIP2025 sharing how CyPath® Lung helps detect lung cancer early, when treatment is most effective.
Grateful for the conversations, collaborations & commitment to advancing lung health.
#LungCancer #EarlyDetection #CyPathLung #PatientCare

CyPath Lung @cypathlung.bsky.social · Aug 13

Looking forward to connecting at AABIP 2025 Conference 8/14. Visit Booth 44 to learn how physicians use CyPath® Lung as a noninvasive diagnostic tool to support early detection of lung cancer and improve patient care.
#CyPathLung #LungCancer #EarlyDetection #AABIP2025 #PatientCare

CyPath Lung @cypathlung.bsky.social · Aug 12

When a CyPath® Lung sample delay arose, our team jumped into action, ensuring safe, timely delivery to the lab. When patient care is at the heart of our team, it can’t skip a beat. ❤️
#CyPathLung #LungCancer #PrecisionPathology #Teamwork #PatientCare

CyPath Lung @cypathlung.bsky.social · Aug 11

Make sure to register at aabipconference.com/registration/

Registration | AABIP 2025

Registration for AABIP 2025 , the leading Conference of American Association for Bronchology and Interventional Pulmonology, Austin, August 14-16, 2025.

aabipconference.com

CyPath Lung @cypathlung.bsky.social · Aug 11

Only 2 days until AABIP! Visit us at Booth 44 to hear how CyPath® Lung is helping physicians detect lung cancer early, noninvasively, and with accuracy you can trust.
We’ll see you there!
#CyPathLung #LungCancer #EarlyDetection #AABIP

1

CyPath Lung @cypathlung.bsky.social · Aug 1

With something as essential as breath, every moment matters.
Early detection saves lives. Let’s keep pushing for awareness and action.
#WorldLungCancerDay #EarlyDetection #LungCancerAwareness #CyPathLung

1

CyPath Lung @cypathlung.bsky.social · Jul 29

“CyPath® Lung gave us the clarity we needed to act early,” said Dr. Gordon Downie, CMO, referring to a Stage 1A mucinous adenocarcinoma missed by other diagnostics.
Every early diagnosis is a life potentially saved.
Read the press release: bit.ly/4l6uOvn
#CyPathLung #LungCancer #bioAffinity

1 1

CyPath Lung @cypathlung.bsky.social · Jul 24

New case study: noninvasive CyPath® Lung detected a Stage 1A neuroendocrine tumor that PET, bronchoscopy & serum markers missed, leading to timely surgical removal.
Noninvasive. Precise. Life saving.
Full PR: bit.ly/44MjPCz
#LungCancer #EarlyDetection #CyPathLung #PhysicianHighlights

CyPath Lung @cypathlung.bsky.social · Jul 22

Canada awards patent for CyPath® Lung, expanding global protection of our noninvasive test for early lung cancer detection. With 92% sensitivity and 88% accuracy, early diagnosis can save lives. PR: bit.ly/CanadaPatent
#CyPathLung #LungCancer #Diagnostics #Biotech #Canada

Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company’s Noninvasive Lung Cancer Diagnostic - bioAffinity

New patent protects market expansion to the north where lung cancer is leading cause of cancer deaths SAN ANTONIO, TX — July 22, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechn...

bit.ly

1

CyPath Lung @cypathlung.bsky.social · Jul 17

CyPath® Lung gives physicians timely, actionable insights for patients at risk of lung cancer. Early detection is critical and fast results save lives.
Noninvasive. Accurate Results.
See how Dr. Nadarajah uses CyPath® Lung: bit.ly/DrNadarajah
#CyPathLung #LungCancer #PhysicianHighlights

CyPath Lung @cypathlung.bsky.social · Jul 15

“Securing this IP positions us well for future opportunities in one of the world’s largest and most underserved healthcare markets.”
Maria Zannes, President & CEO
CyPath® Lung has shown 92% sensitivity, 87% specificity
Read the PR: bit.ly/3IuVgS3
#LungCancer #Innovation #EarlyDetection

bioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic - bioAffinity

One third of world’s smokers live in China, which has highest rate of lung cancer SAN ANTONIO, TX — July 15, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advanc...

bit.ly

CyPath Lung @cypathlung.bsky.social · Jul 10

Quick, accurate, and patient-centered.
CyPath® Lung delivers actionable results in just 3 days empowering better clinical decisions, faster.
See what NP Israel Garcia says about its impact on care.

Check it out: bit.ly/IsraelGarcia
#CyPathLung #LungCancer #EarlyDetection #PhysicianHighlights